BOCG named a Top 10 Impact Investment Institution in 2023

From November 28th to 29th, the 2023 Towards the Light Annual Conference was held in Shenzhen, China. The theme of this conference was “ESG and Value Innovation for Sustainable Development, ESG Ecological Conference.” China’s Best Impact Investments of the Year Awards were solemnly announced, with Blue Ocean Capital Group (“BOCG”) winning the “2023 For Good Award | Top 10 Impact Investment Institution”. Dr. Yanling Wen, Chief Medical Officer of BOCG, was invited to participate in a roundtable forum to discuss the challenges and opportunities of ESG impact investment in China with other distinguished guests.

“2023 For Good Award | China’s Best Impact Investments of the Year” was jointly launched by Cyzone, Towards the Light Future, and the China Impact Investment Network (CIIN). The aim is to find leaders of impact investment and to promote solving social issues through business means.

The selection process lasted for four months. Through questionnaire surveys, data analysis, and expert evaluations, “Top 10 Impact Investment Institutions of the Year” and the “Top 10 Best Practices for Impact Investing of the Year” were selected. The expert judging panel scored and ranked institutions based on the information submitted by the applying organizations. BOCG’s excellent performance in the field of impact investment over the past year received high recognition from the expert judging panel, with consideration of BOCG’s impact investment strategy, efforts to improve corporate governance and implementation of ESG factors to the investment process and value-add contributions.

BOCG was recognized as a “2023 For Good Awards | Top 10 Impact Investment Institution”.

As a signatory to the United Nations-supported Principles for Responsible Investment (UN PRI), BOCG has adhered to the principles of responsible investment, with a focus on investing in innovative companies in the healthcare sector. BOCG is devoted to impact investment by incorporating ESG into the entire investment process. BOCG provides ESG training and advice for portfolio companies based on their needs, conducts regular assessments of the ESG performance, and provides improvement suggestions to ensure the control and reduction of significant ESG risks, bringing positive changes to portfolio companies.

• BOCG assisted its portfolio company, Boan Biotech, for new drug development of Boyounuo for four cancer indications, benefiting tens of thousands of patients and saving hundreds of millions of medical expenses compared to original drugs.
• Another BOCG’s portfolio company, Signet Therapeutics, utilizes innovative organoid disease models and founded an organoid animal center. With this advanced technology, Signet Therapeutics has reduced the use of laboratory animals such as mice, rabbits, monkeys, etc., and therefore has significantly improved animal welfare. In the meanwhile, the efficiency and success rate of drug development have been substantially enhanced.
• BOCG has also played a critical role in supporting the establishment of a traceable supply chain system for KOKA Lifesciences, another medical device portfolio company, in Qinghai. BOCG helped KOKA Lifesciences improve  its compliance with relevant international standards in the medical device industry, and build an sustainable  ecosystem and benefit local people in the rural country.

Mr. Frank Yang, founding partner and CEO of BOCG, stated, “We appreciate the For Good Awards and the recognition! Since joining UN PRI, BOCG has gradually built up its internal ESG system. We wish to invest and support companies with true innovation that can bring changes and benefits to society. As a signing party of UN PRI and participant in promoting the development of the healthcare sector, we will continue to work hand in hand with portfolio companies for better drugs and therapeutics to enhance people’s health and well-being.

‍